O

Optomed Oyj
OMXH:OPTOMED

Watchlist Manager
Optomed Oyj
OMXH:OPTOMED
Watchlist
Price: 3.81 EUR -0.26% Market Closed
Market Cap: 75m EUR
Section:
 

Relative Value

The Relative Value of one OPTOMED stock under the Base Case scenario is 4.97 EUR. Compared to the current market price of 3.81 EUR, Optomed Oyj is Undervalued by 23%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

OPTOMED Relative Value
Base Case
4.97 EUR
Undervaluation 23%
Relative Value
Price
O
Worst Case
Base Case
Best Case

Valuation Multiples

4.3
P/S
P/S
Price to Sales
4.3
vs History
65
vs Industry
26
Median 3Y
4.5
Median 5Y
5
Industry
2.3
Forward
4.2
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
Median 3Y
-12.8
Median 5Y
-14.6
Industry
22.5
Forward
-33.9
More Details
Negative
P/OCF
P/OCF
Price to OCF
N/A
vs History
vs Industry
Median 3Y
-46.4
Median 5Y
-45.3
Industry
14.5
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
Median 3Y
-12.3
Median 5Y
-12.4
Industry
21.5
More Details
3.7
P/B
P/B
Price to Book Value
3.7
vs History
41
vs Industry
27
Median 3Y
3.4
Median 5Y
3.6
Industry
2.2
More Details
4.1
EV/S
EV/S
Enterprise Value to Sales
4.1
vs History
68
vs Industry
26
Median 3Y
4.2
Median 5Y
4.7
Industry
2.6
Forward
4
More Details
6.3
EV/GP
EV/GP
Enterprise Value to Gross Profit
6.3
vs History
68
vs Industry
31
Median 3Y
6.6
Median 5Y
7.2
Industry
5.2
More Details
Negative
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
N/A
vs History
vs Industry
Median 3Y
-29.5
Median 5Y
-31.1
Industry
11.9
Forward
-34.9
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
Median 3Y
-12.7
Median 5Y
-13.7
Industry
16.9
Forward
-16.1
More Details
Negative
EV/OCF
EV/OCF
Enterprise Value to OCF
N/A
vs History
vs Industry
Median 3Y
-41.7
Median 5Y
-41.7
Industry
14.7
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
Median 3Y
-17.2
Median 5Y
-18
Industry
18.7
More Details
4
EV/IC
EV/IC
Enterprise Value to IC
4
vs History
44
vs Industry
21
Median 3Y
3.7
Median 5Y
3.9
Industry
1.9
More Details

Multiples Across Competitors

OPTOMED Competitors Multiples
Optomed Oyj Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
FI
Optomed Oyj
OMXH:OPTOMED
74.9m EUR 4.3 -13 -23.7 -12.8
US
Abbott Laboratories
NYSE:ABT
213.5B USD 4.9 15.3 19.5 27.1
US
Intuitive Surgical Inc
NASDAQ:ISRG
199.6B USD 20.8 72.7 55.7 67.9
US
Boston Scientific Corp
NYSE:BSX
137.2B USD 7.1 49.1 28.8 39.2
US
Stryker Corp
NYSE:SYK
134.5B USD 5.5 45.7 22.3 27
IE
Medtronic PLC
NYSE:MDT
128.6B USD 3.7 27 15.2 21.9
DE
Siemens Healthineers AG
XETRA:SHL
48.3B EUR 2.1 22.5 12.8 18.1
US
IDEXX Laboratories Inc
NASDAQ:IDXX
56B USD 13.4 54.5 39.2 43.4
US
Becton Dickinson and Co
NYSE:BDX
56.4B USD 2.6 33.6 12.4 21.2
US
Edwards Lifesciences Corp
NYSE:EW
48.8B USD 8.3 35.7 25.5 27.9
US
GE Healthcare Technologies Inc
NASDAQ:GEHC
38.2B USD 1.9 17.2 12.9 15.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
FI
O
Optomed Oyj
OMXH:OPTOMED
Average EV/EBITDA: 24.4
Negative Multiple: -23.7 		N/A N/A
US
Abbott Laboratories
NYSE:ABT
19.5
12%
1.6
US
Intuitive Surgical Inc
NASDAQ:ISRG
55.7
26%
2.1
US
Boston Scientific Corp
NYSE:BSX
28.8
22%
1.3
US
Stryker Corp
NYSE:SYK
22.3
13%
1.7
IE
Medtronic PLC
NYSE:MDT
15.2
8%
1.9
DE
Siemens Healthineers AG
XETRA:SHL
12.8
11%
1.2
US
IDEXX Laboratories Inc
NASDAQ:IDXX
39.2
14%
2.8
US
Becton Dickinson and Co
NYSE:BDX
12.4
9%
1.4
US
Edwards Lifesciences Corp
NYSE:EW
25.5
13%
2
US
GE Healthcare Technologies Inc
NASDAQ:GEHC
12.9
10%
1.3

See Also

Summary
OPTOMED intrinsic value, competitors valuation, and company profile.
DCF Valuation
OPTOMED stock valuation using Discount Cash Flow valuation method.
Relative Valuation
OPTOMED stock valuation using valuation multiples.
Wall Street Estimates
OPTOMED price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
OPTOMED stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 302,100+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.